Conflicts of interest Bayer LFB BMS-Pfizer Octapharma - PowerPoint PPT Presentation

29/11/2013 How do I treat massive bleeding? Red blood cell / plasma / platelet ratio and massive transfusion protocols Anne GODIER Service d’Anesthésie-Réanimation Hopital Cochin Paris G roupe d’ I ntérêt en H émostase P ériopératoire 1

29/11/2013 Conflicts of interest  Bayer  LFB  BMS-Pfizer  Octapharma  Boehringer-Ingelheim  CSL-Behring  Léo  Sanofi Acknowledgement  Pr Sophie Susen (Lille) 2

29/11/2013 1:1:1 ratio 3

29/11/2013 Massive bleeding Severe trauma Post-partum haemorrhage Major surgery (cardiac & aortic surgery) Gastrointestinal bleeding Liver transplantation Massive transfusion Mortality Coagulopathy 4

29/11/2013 Trauma-induced coagulopathy trauma patient Massive bleeding Fluid loading Shock Massive RBC transfusion Acidosis Hypothermia Dilution Trauma induced Trauma-induced Coagulopathy coagulopathy coagulopathy Adapted from Brohi K, Ann Surg 2007* 5

29/11/2013 Trauma-induced coagulopathy trauma patient Massive Tissue Injury bleeding Fluid loading Shock Massive RBC transfusion Acidosis Hypothermia Dilution Acute traumatic coagulopathy Trauma induced Trauma-induced Coagulopathy coagulopathy coagulopathy Adapted from Brohi K, Ann Surg 2007* 6

29/11/2013 Trauma-induced coagulopathy trauma patient Massive Tissue Injury bleeding Inflammation Fluid loading Shock Fibrinolysis Massive RBC transfusion systemic platelet anticoagulation dysfonction activated protein C Acidosis Hypothermia Dilution Acute traumatic coagulopathy Trauma induced Trauma-induced Coagulopathy coagulopathy coagulopathy Adapted from Brohi K, Ann Surg 2007* 7

29/11/2013 Trauma-induced coagulopathy trauma patient Massive Tissue Injury bleeding Inflammation Fluid loading Shock Fibrinolysis Massive RBC transfusion systemic platelet anticoagulation dysfonction activated protein C Acidosis Hypothermia Dilution Acute traumatic coagulopathy Trauma induced Trauma-induced Coagulopathy coagulopathy coagulopathy Adapted from Brohi K, Ann Surg 2007* 8

29/11/2013 Early onset of coagulopathy in trauma o On-scene: TAC = trauma-associated coagulopathy injury On-scene Normal Non-overt TAC TAC 20 (44%) 22 (49%) 3 (7%) Admission Normal Non-overt TAC TAC Normal Non-overt TAC TAC Normal Non-overt TAC TAC 16 (36%) 3 (7%) 1 (2%) 16 (36%) 15 (33%) 5 (11%) 0 (0%) 0 (0%) 3 (7%) On-scene and trauma resuscitation room coagulation status Floccard B , et al. Injury 2012;43:26–32 9

29/11/2013 Reduced Coagulation Factor Activity FII FV FVII FIX FX FXI Facteur Severe trauma patients Jansen JO, J Trauma 2011 10

29/11/2013 10-15 mL/kg 30 mL/kg Fibrinogène g/L +0.4 +1.0 II % +16 +41 V % +10 +28 VII % +11 +38 IX % +8 +28 X % +15 +37 XI % +9 +23 XII % +30 +44 Br J Haematol 2004;125:69-73 11

29/11/2013 10-15 mL/kg 30 mL/kg Fibrinogène g/L +0.4 +1.0 II % +16 +41 V % +10 +28 VII % +11 +38 IX % +8 +28 X % +15 +37 XI % +9 +23 XII % +30 +44 Br J Haematol 2004;125:69-73 12

29/11/2013 Plasma  coagulation factors  fibrinogen  1 FFP = 400 mg of fibrinogen  proteins, including immunoglobulins and albumin  volume expansion with high oncotic pressure  Preclinical studies  less pro-inflammatory than artificial colloids  protective effects on endothelial permeability and vascular stability Pati S. J Trauma 2010; 69 Suppl 1:S55-63. 13

29/11/2013 Increasing plasma:RBC ratio  Transfusion with high ratio  Ratio = plasma number / RBC number 14

29/11/2013 1:1.4 246 trauma patients with massive transfusion FFP:RBC 1:2.5 mortality 1:8 (>10 RBC) 15

29/11/2013 1:1.4 246 trauma patients with massive transfusion FFP:RBC 1:2.5 mortality 1:8 (>10 RBC) 16

29/11/2013 Military trauma studies: beneficial effect of high FFP:RBC ratio 17

29/11/2013 military civilian trauma studies 18

29/11/2013 Mortality in patients undergoing massive transfusion n=3400 19

29/11/2013 Mortality in patients undergoing massive transfusion n=3400 20

29/11/2013 Limitations  retrospective studies (or cohort studies)  missing data  analytical bias  survival bias 21

29/11/2013 april 2013 Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. Recommendation 26 We recommend the initial administration of plasma [fresh frozen plasma (FFP) or pathogen-inactivated plasma] (Grade 1B) or fibrinogen (Grade 1C) in patients with massive bleeding. If further plasma is administered, we suggest an optimal plasma:red blood cell ratio of at least 1:2. (Grade 2C) 22

29/11/2013 Platelet : RBC ratio? 23

29/11/2013 The prevalence of abnormal results of conventional coagulation tests on admission to a trauma center Hess JR, Lindell AL, Stansbury LG, Dutton RP, Scalea TM.Transfusion. 2009;49:34-9 Records of all patients admitted to a large urban trauma center during 2000 through 2006 N=23 000 24

29/11/2013 25

29/11/2013 Retrospective data regarding platelet transfusion mortality variation between trauma receiving large amount of platelets copared to small amount % 26

29/11/2013 Retrospective data regarding platelet transfusion % mortality mortality variation between trauma receiving large amount of platelets copared to small amount % low high ratios ratios 27

29/11/2013 april 2013 Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. We recommend that platelets be administered to maintain a platelet count above 50 × 10 9 /l. (Grade 1C) We suggest maintenance of a platelet count above 100 × 10 9 /l in patients with ongoing bleeding and/or TBI. (Grade 2C) UPDATED GUIDELINES TEMPORARY VERSION Increasing platelet:RBC ratio is associated with a mortality decrease For massive transfusion platelet units must be part of the second transfusion package Platelets must be transfused with a platelet:RBC ratio between 1:5 and 1:1. This ratio may be close to 1:1 28

29/11/2013 Increasing ratios is not enough 1:1:1 Ratio : a time-dependent variable t 29

29/11/2013 Ratio = FFP / RBC Deficit = RBC - FFP * ≤ 2 >6 O Mortality of trauma patients grouped by deficit status 30

29/11/2013 Reducing transfusion delay carefully constructed massive transfusion protocol  local agreement with the blood bank  products available as soon as possible  healthcare professionals 31

29/11/2013 Protocol : 10 RBC 4 FFP 2 platelets  ratio 1:2.5 * * 32

29/11/2013 Reducing transfusion delay carefully constructed massive transfusion protocol  local agreement with the blood bank  products available as soon as possible  healthcare professionals  which blood products?  number?  sequence?  transfusion package 33

29/11/2013 Packs Godier A, Samama M, Susen S. Curr Opin Anesthesiol 2012 34

29/11/2013 Packs Godier A, Samama M, Susen S. Curr Opin Anesthesiol 2012 35

29/11/2013 Immediate availability of plasma in the 1 st pack Thawing plasma thawed AB group plasma radio wave-based Freeze-dried plasma stored for immediate availability thawing technology together with O group RBC 36

29/11/2013 1:1:1 ratio in blood transfusion: many argues in massive transfusion non massively transfused patients? 37

29/11/2013 Mortality in patients undergoing surgery without massive transfusion 38

29/11/2013 overall complications  increase in complications  no improvement in survival   in complications as  volumes of plasma number of units of plasma transfused in 12 hours 39

29/11/2013 Conclusion: Management of massive bleeding  A growing body of evidence supports that high ratios improve outcome  Only in massive bleeding   minority of patients  Only a small aspect of massive bleeding management  immediate delivery of blood products  through pre-established protocols  FFP/PLT/RBC ratios matter to define the content of packs immediately available within the golden hour. 42

Conflicts of interest Bayer LFB BMS-Pfizer Octapharma - PowerPoint PPT Presentation

29/11/2013 How do I treat massive bleeding? Red blood cell / plasma / platelet ratio and massive transfusion protocols Anne GODIER Service dAnesthsie-Ranimation Hopital Cochin Paris G roupe d I ntrt en H mostase P

Conflicts of Interest Disclosure No conflicts of interest

Conflicts of Interest I have no financial conflicts of interest to disclose that are

Conflicts of Interest: Dealing with the Inevitable! Conflicts of Interest: Dealing with the

Conflicts of Interest Update in the Diagnosis, No Conflicts of Interest Treatment and

Conflicts of Interest Dr. Ehret has no actual or potential conflicts of interest and no

Conflicts of interest The speaker has no conflicts of interest to disclose. Learning objectives

Conflicts of Interest Conflicts of Interest Cluj-Napoca, Romania under EU under EU 27 November

Agenda Objectives 4:15 Introduction to Todays Forum (Lusk) 1. Identify the basic knowledge,

Be Sensitive to, and Manage, Conflict of Interest Situations! 1 Conflicts of Interest:

The Range of Conflicts of Interest and how they should be managed Dr Neville Gibbs Department of

Conflicts of Interest No Financial Conflicts Biases, favorable toward: Bio psycho

Professional Commitment of Faculty and Conflicts of Interest and Conflicts of Commitment 1

Conflict of Interest I have no conflicts of interest to report Evaluation of Motivational

Conflicts of Interest Universal Coverage Strategies in California I have no financial conflicts.

Conflicts of Interest Tufts University School of Medicine Effective April 5, 2010 1 Industry

Policy on Conflicts of Interest Tal Sagorsky, EFA FTI Secretariat FTI Board Meeting 18 19

2017-10-29 Conflicts of interest and funding Biologics I have received lecture fees from:

Presentation Overview Discuss how to recognize and manage conflicts of interest Introduce

Conflict of Interest The Problems with the NICHD Categories of FHR I have no conflicts of

Palumbo Antonio, MD Research Support/P.I. No relevant conflicts of interest to declare Employee

Forest Carbon Partnership Facility Conflicts of Interest FCPF Participants Committee Meeting

I HAVE NO CONFLICTS OF INTEREST Page 1 Vitamins / supplements to be covered Antioxidants

Managing Conflicts of Interest AFOA BC Conference Dec 6, 2018 1 Learning Objectives What

I have no conflicts of interest to disclose. 2 1 10/8/2018 it will 4 2 10/8/2018 5 The